

Cellnovo expands partnership with Flex as it begins high-volume manufacturing of its connected all-in-one diabetes management system

Paris, France, September 29, 2015 – Cellnovo Group (“Cellnovo”), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, today announced the launch of its extended high-volume manufacturing partnership with Flex (formerly Flextronics), for the production and assembly of Cellnovo disposable insulin cartridges. As a global sketch-to-scale™ solutions company that designs and builds intelligent products for a connected world, Flex is the ideal partner to support Cellnovo take the manufacturing of its product to the next level.

The expanded partnership is the continuation of a strong relationship established in 2013, when Cellnovo partnered with the Flex Medical design team in Milan, working on the design and industrialization of Cellnovo’s cartridges. Cellnovo has recently made significant capital and expense investments in the partnership, including tooling for cleanroom-moulded components from Flex’s European Centre of Excellence for precision plastics in Zurich. Assembly equipment will be built at Flex’s FDA-registered Centre of Excellence for automation in Althofen, Austria, with assembly lines tailored and sized to meet Cellnovo’s business needs.

Drawing upon its proven world-class supply chain solutions expertise, Flex will provide all manufacturing services, meeting applicable quality and regulatory requirements. Shipments of subassemblies to Cellnovo’s plant in Wales are expected to begin later this year, with finished products in the second quarter of 2016.

Eric Beard, Executive Chairman of Cellnovo, commented: *“Thanks to the proceeds from our recent IPO on Euronext, we can now start our high-volume manufacturing programme with Flex, enabling us to economically scale up production to support our market growth.”*

“Flex is proud to be Cellnovo’s sketch-to-scale product solutions partner and help them to meet the demands of their growing customer base,” said Mark Kemp, president of the Medical group at Flex. *“Cellnovo is a leading innovator in this growing segment of insulin patch pumps, with a unique pumping technology.”*

About Flex

Flextronics International Ltd. (Reg. No. 199002645H) is a leading sketch-to-scale™ solutions company that designs and builds intelligent products for a connected world. With more than 200,000 professionals across 30 countries and a promise to help make the world Live smarter™, the company provides innovative design, engineering, manufacturing, real-time supply chain insight and logistics services to companies of all sizes in various industries and end-markets. For more information, visit www.flextronics.com or follow us on Twitter @Flextronics.

About Cellnovo

Cellnovo (Euronext, FR 0012633360 - CLNV) is an innovative medical device company specialising in diabetes. Cellnovo has developed and markets the first connected all-in-one diabetes management system based on a patch pump that helps make life easier for patients. With its unique device Cellnovo allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time. The system has CE mark, is reimbursed in most countries and is already being marketed in France and the United Kingdom.



The First Connected All-in-one Diabetes Management System

For further information please visit www.cellnovo.com

Contact

Cellnovo

Sophie Baratte
investors@cellnovo.com

Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV

NewCap

Investor Relation
Emmanuel Huynh
cellnovo@newcap.fr
+ 33 1 44 71 94 92



NewCap

Media Relations
Nicolas Merigeau
cellnovo@newcap.fr
+33 1 44 71 94 98